RxDoctor Payments Data

Anna Juern, MD

Dermatology · Sacramento, CANPI 1467654673

Payments from drug & device makers

$806in general payments, 2019–2025

Across 9 payments — averaging $89.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$309
  • Amgen$237
  • Sanofi$125
  • UCB, Inc.$108
  • AbbVie$27

What the payments were for

  • Food & beverage$806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$309
Amgen1$237
Sanofi3$125
UCB, Inc.1$108
AbbVie1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$806 in reported general payments places this provider in the 35th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$213,372
Medicare patients
481
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast24$123,176
Dupixent PenDupilumab12$41,690
Tacrolimus64$8,275
Clobetasol Propionate129$5,970
Ketoconazole384$5,814
Triamcinolone Acetonide222$2,612
Metronidazole36$2,195
Fluorouracil27$1,866
Betamethasone Dipropionate36$1,411
Doxycycline Hyclate25$1,163
Fluocinonide27$908
Tretinoin15$901
Clindamycin Phosphate15$744
Clindamycin Phos-Benzoyl PeroxClindamycin Phos/Benzoyl Perox17$557
Doxycycline Monohydrate15$527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$237$123,17624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,875 dermatology providers in California.

Other dermatology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →